Valuation: Apogee Therapeutics, Inc.

Market Cap 9.94B 8.7B 8.03B 7.5B 14.11B 941B 14.37B 96.35B 37.39B 463B 37.34B 36.5B 1,616B P/E 2026 *
-30.7x
P/E 2027 * -23.8x
Enterprise Value 8.96B 7.85B 7.24B 6.76B 12.72B 848B 12.95B 86.86B 33.71B 418B 33.66B 32.9B 1,456B EV / Sales 2026 *
986x
EV / Sales 2027 * 736x
Free-Float
87.2%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day+0.09%
1 week+0.14%
Current month+61.59%
1 month+61.59%
3 months+70.56%
6 months+73.78%
Current year+75.85%
1 week 132.55
Extreme 132.55
133
1 month 77.1
Extreme 77.1
133.16
Current year 60.35
Extreme 60.35
133.16
1 year 34.34
Extreme 34.34
133.16
3 years 14.19
Extreme 14.19
133.16
5 years 14.19
Extreme 14.19
133.16
10 years 14.19
Extreme 14.19
133.16
Manager TitleAgeSince
Chief Executive Officer 36 01/09/2022
Director of Finance/CFO 60 01/01/2023
Chief Tech/Sci/R&D Officer - 01/05/2023
Director TitleAgeSince
Director/Board Member 54 22/06/2023
Director/Board Member 62 01/06/2023
Director/Board Member 36 01/06/2023
Date Insider Type Main position Quantity % Market Cap.
06-22Sell

Chief Executive Officer

-80,000 0.1429%
06-22Sell

Chief Technology Officer

-26,400 0.0471%
06-10Sell

Chief Executive Officer

-20,000 0.0357%
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+0.14%+205.97% - 9.94B
+1.15%+9.07%-3.67%+4.36% 46.62B
-2.77%+12.95%+407.40%+614.26% 40.95B
-0.03%+15.14%+22.70%-12.74% 32.26B
-1.73%+4.85%+18.15%+59.57% 32.24B
-3.29%+2.85%+13.80%+30.30% 25.53B
+1.15%+16.98% - - 16.38B
-0.96%+16.22%+70.46%+125.41% 15.27B
+0.56%+8.00%+12.65%+21.35% 13.61B
-1.74%+4.48%+99.22%+92.87% 13.34B
Average -0.76%+9.30%+94.07%+116.92% 24.61B
Weighted average by Cap. -0.86%+9.95%+99.24%+141.41%

Financials

2026 *2027 *
Net sales 9.09M 7.96M 7.35M 6.86M 12.9M 860M 13.14M 88.13M 34.2M 424M 34.15M 33.39M 1.48B 12.5M 10.95M 10.1M 9.43M 17.74M 1.18B 18.07M 121M 47.03M 583M 46.96M 45.91M 2.03B
Net income -318M -278M -257M -240M -451M -30.05B -459M -3.08B -1.19B -14.81B -1.19B -1.17B -51.61B -416M -365M -337M -314M -591M -39.42B -602M -4.04B -1.57B -19.42B -1.56B -1.53B -67.69B
Net Debt -980M -858M -792M -739M -1.39B -92.71B -1.42B -9.5B -3.69B -45.68B -3.68B -3.6B -159B -740M -648M -598M -558M -1.05B -70.06B -1.07B -7.18B -2.79B -34.52B -2.78B -2.72B -120B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
30/06/26 $132.73 +0.09% 5,393,506
29/06/26 $132.61 +0.05% 3,494,734
26/06/26 $132.55 -0.10% 5,109,502
25/06/26 $132.68 -0.01% 4,952,655
24/06/26 $132.69 -0.14% 7,739,644
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
132.73USD
Average target price
130.53USD
Spread / Average Target
-1.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock